whether it may exert a chemoprotective effect on the bowel to prevent colonic dysplasia and colon cancer in patients with coexisting IBD. [13] [14] [15] [16] [17] [18] It has no effect on symptoms such as pruritus, abdominal pain, and fatigue. In this review we will (1) examine the potential pathogenesis of PSC that can direct potential therapies, (2) discuss the difficulties in designing and conducting interventional studies in PSC, (3) briefly describe the drugs that have already been unsuccessfully trialed in PSC, and (4) evaluate the possible therapeutic benefits and mechanisms of the novel agents currently being developed and trialed for the future management of this potentially devastating condition. A summary of the various agents mentioned in this article according to pathogenic target is provided in ►Fig. 1.
Pathogenesis
As mentioned earlier, the etiology of PSC is not clear. Genetic factors appear to play an important role, as initially demonstrated by candidate gene studies up to 30 years ago, and subsequently confirmed by recent GWASs and Immunochip studies. [19] [20] [21] These studies confirm a strong association with risk loci on chromosome 6 that pertain to the MHC, especially HLA-B8 and HLA-DR3. A further 15 non-HLA risk loci have been identified, including FUT-2 involved in regulating bacteria in the intestine and interleukin-2 loci and other genes found in other autoimmune diseases. These genetic studies have emphasized the importance of the acquired and innate immune responses and interaction with the biome, in the pathogenesis of PSC.
Other factors are believed to play a role in the etiology, such as a toxic effect of bile on damaged biliary epithelium; the so-called leaky gut theory, where preexisting IBD predisposes to increased bowel wall permeability and therefore increased exposure of the bile ducts to bacteria and other pathogens and toxins; and also an increase in homing T cells and other cytokines from the bowel to the liver, involving upregulation of VAP-1, CCR9, and various other chemokines. 22, 23 The pathogenesis of PSC is discussed in more detail in a recent review.
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Challenges of Designing Trials in Primary Sclerosing Cholangitis
There are many barriers to designing and carrying out a successful clinical trial in PSC, which may be one of the factors that an effective medical therapy remains elusive. First, PSC is a rare disease, with a prevalence varying from 0.22 per 100,000 population to 16.2 per 100,000 population and an incidence of 0.04 to 1.31 per 100,000 person-years. 25, 26 This makes recruitment of sufficient patients for an adequately powered trial challenging; national and often international multicenter trials are usually required. Second, the median time in the natural history of PSC to clinically meaningful endpoints, such as liver transplantation or death, is 10 to 21 years, which is not feasible for a clinical Fig. 1 A schematic representation of the various elements contributing to pathophysiology of primary sclerosing cholangitis PSC (colored boxes), and the therapeutic agents, listed above, which may be directed against this particular element. Agents in italics are still in development and are not licensed. PAMP, pathogen-associated molecular patterns; MΦ, monocyte; TLR, toll-like receptors; BE, biliary epithelium; Th1, T-helper 1; LOXL2, lysyl oxidase-like 2; BA, bile acid; PL, phospholipid; MDR3, multidrug resistance 3 gene; CFTR, cystic fibrosis transmembrane conductance; TGR5, G-protein coupled receptor; UDCA, ursodeoxycholic acid; atRA, all-trans retinoic acid; PSC, primary sclerosing cholangitis. (Adapted from a figure courtesy of Chris Bowlus, University of California, Davis, CA.) trial. Large cohorts of up to 7,000 PSC patients are currently being investigated studying the phenotype of a patient with their genotype and the relationship to prognosis. This will help to stratify their clinical care (e.g., more aggressive management for those with a poor prognosis, such as early inclusion in clinical trials of novel agents); in addition, it will also help direct specific therapies for specific phenotypes. In the context of designing a clinical trial of new therapeutic agents in PSC, the differing phenotypes among the study population can lead to an underpowered trial and the possibility of a type II error of what may potentially have been a beneficial agent.
Previous Trials in Primary Sclerosing Cholangitis Ursodeoxycholic Acid
Ursodeoxycholic acid is a hydrophilic dihydroxy bile acid that makes up 3% of endogenous human bile acids, but as a drug is used to good effect in various cholestatic liver conditions, particularly primary biliary cholangitis (PBC; formerly known as primary biliary cirrhosis). As mentioned above, UDCA has been shown to reduce ALP in PSC. Between 1991 and 2009, there have been 11 clinical trials evaluating varying doses of UDCA in PSC (from 8 mg/kg/d up to 30 mg/kg/d), 9 of which have been placebo controlled and the majority double blinded. [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] In 10 of the 11 trials, an improvement in liver biochemistry was shown, but none has shown a survival benefit or symptomatic improvement. The duration of these trials varies from 1 to 5 years, and the number of patients enrolled range from 12 to 219. The most recent large trial of 150 patients looked at high-dose UDCA (28-30 mg/kg) versus placebo, and in fact showed an adverse outcome in PSC, with increased mortality in the UDCA group. 43 This surprising result, which was in conflict with the previous smaller studies of UDCA in lower doses, has caused increased caution over the use of UDCA in PSC, particularly in high doses, and has brought a halt to further studies of UDCA in PSC. It is worth noting that, compared with other studies of UDCA in PSC, there was not as significant a biochemical response to UDCA as compared with placebo. Whether this reflects a problem with compliance is not clear, and it is also unclear whether the results truly reflect an adverse effect of the UDCA. Recently, it was shown that withdrawal of UDCA in patients with PSC causes a rebound rise in ALP (76% increase), which supports a potential benefit of UDCA. 45 A treatment algorithm for judicious use of UDCA in PSC has been proposed, although it is not validated.
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There is also under way a trial of UDCA in children and adolescents, given that this disease behaves in a slightly different and more aggressive manner than adult-onset disease and there has been a lack of prior trials of UDCA in the pediatric population. 
All-Trans Retinoic Acid
All-trans retinoic acid (atRA) is a derivative of vitamin A, and has various anti-inflammatory and immune modulatory properties. It is currently licensed for inflammatory conditions such as rheumatoid arthritis and psoriasis, as well as a treatment in acute promyelocytic leukemia. An animal study showed that combination treatment of atRA with UDCA, as compared with either atRA or UDCA alone, in bile duct ligated mice significantly reduce liver fibrosis on histology, reduced the expression of marker genes for liver fibrosis, duct proliferation, and inflammation and reduced hepatic bile acid pool levels. 67 Accordingly, a phase I clinical trial is currently underway of atRA in patients with PSC.
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Altering Bile Acid Composition norUrsodeoxycholic Acid 24-norUrsodeoxycholic acid (norUDCA) is a synthetic bile acid with a similar structure to UDCA, but with one fewer methylene in its side chain. From animal studies, again using the Abcb4 (À/À) model, formally called Mdr2 (À/À), it appears to have multiple effects on biliary physiology. As compared with UDCA, norUDCA has a relative resistance to conjugation, and a proportion of unconjugated norUDCA is secreted into the canaliculi, promptly pronated by a hydrogen ion, and then reabsorbed back into the cholangiocyte, thereby generating a bicarbonate ion, and then is secreted back into the bile via the hepatocyte. This repeated pathway through the hepatocyte, a so-called cholehepatic shunt, sets up a bile acid-dependant, bicarbonate-rich choleresis, which in mouse models appears to have a beneficial effect on fibrosis and other biliary processes, unlike the choleresis promoted by UDCA (see ►Fig. 3). 69,70 A phase II double-blind, placebo-controlled randomized trial of norUDCA in PSC is currently underway.
71
Apical Sodium-Dependent Bile Acid Transporter Inhibitors
Another novel therapeutic strategy altering bile acid composition and flow is to reduce the exposure of biliary epithelia to supposedly toxic bile acids by inhibiting their reabsorption in the ileum. This can be potentially achieved by inhibiting the apical sodium-dependent bile acid transporter (ASBT), a transmembrane protein localized on the luminal surface of ileal enterocytes, which is the predominant pathway for bile acid active reabsorption from the lumen into the enterocyte. Studies in the Abcb4 (À/À) mouse model have shown that inhibition of ASBT brings about reduced hepatic profibrogenic gene expression, an upregulation of anti-inflammatory and antifibrogenic genes, and a reduction in bile acid pool size and composition in the liver, with improved liver histology and a reduction in the extent of fibrosis.
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A potential dose-limiting side effect of inhibiting bile acid reabsorption, given this increases the fecal bile acid load, is diarrhea. A phase II clinical trial in PSC is currently underway with ASBT inhibitor SHP625 (formerly LUM001), and this drug is also being assessed in trials of pruritus in PBC.
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Peroxisome Proliferator-Activated Receptor-α Agonists
There is current interest in bezafibrate as a potentially effective therapeutic agent in cholestatic liver diseases including PBC and PSC. Bezafibrate acts as a ligand of peroxisome proliferator-activated receptor α (PPARα), an intranuclear receptor involved in lipid metabolism.
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Peroxisome proliferator-activated receptor α promotes the expression of the multidrug resistance 3 (MDR3) gene, and increases P-glycoprotein levels in bile duct canaliculi. In turn, P-glycoprotein increases the phospholipid levels in bile juice, which forms micelles with toxic hydrophobic bile acids, thereby helping to prevent damage to bile ducts.
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There is increasing evidence for efficacy of bezafibrate in PBC, with a current large placebo-controlled clinical trial of bezafibrate underway in PBC. 76 There have been four small retrospective case reports of bezafibrate lowering liver enzymes in PSC, [77] [78] [79] [80] and recently a small Japanese prospective
single-arm open-label study of 11 patients also showed some efficacy after 12 weeks of bezafibrate in PSC. 81 All patients had improvements of their ALP and gamma-glutamyl transferase, with 64% also having improvement in transaminases.
It must be noted that only 2 of 11 patients had concomitant ulcerative colitis, and whether these results can be reproduced in other populations of PSC remains to be seen, but further trials are warranted. New Therapeutic Strategies for Primary Sclerosing Cholangitis Williamson, Chapman 9 Manipulating Gut-Homing Immune Cells
There is mounting evidence that gut-homing T cells may play a role in the pathogenesis of PSC, in keeping with the common coexistence of IBD with PSC. Expression of chemokine receptor CCR9, along with the integrin α4β7, normally is induced on the cell surface of T lymphocytes primed in mesenteric lymph nodes, imprinting them with the capacity to travel to the gut and take up residence in the intestinal lamina propria. 82 This migration into the tissue involves CCR9 first recognizing and binding to its ligand, CCL25, which is constitutively expressed in the small intestine. This interaction causes the T cell to bind to and roll along the endothelium, and it causes activation of α4β7 on the T-cell surface, which then binds to its ligand mucosal addressin cell adhesion molecule-1 (MAdCAM-1). Other adhesion molecules besides MAdCAM-1 are involved in recruitment of effector T cells to the gut, especially in inflammation, including vascular adhesion protein-1 (VAP-1), which is not only an adhesion molecule, but also an ectoenzyme with potent amine oxidase activity. This arrests the T lymphocyte, and it is extruded through the epithelium into the lamina propria where it may carry out its functions (see ►Fig. 4).
Ordinarily, the expression of MAdCAM-1 and CCL25 is restricted to the intestinal endothelium, rendering CCR9þ T cells fairly specific for the gut, with no expression in the liver. However, it has been shown in human PSC explants that there is aberrant expression of MAdCAM-1 and CCL25, and approximately 20% of the intrahepatic T cells are CCR9þ α4β7þ, while there are virtually no CCR9þ α4β7þ T cells present in healthy livers and other liver-disease controls. 23, 83 The explanation for these findings is unknown, but may involve activation of the enzymatic activity of VAP-1 and upregulated expression of MAdCAM-1 on the hepatic sinusoidal epithelium, thus facilitating recruitment of these cells into the liver.
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There are multiple agents currently available or in development that target various aspects of this pathway. Vedolizumab is a monoclonal antibody against α4β7, which is currently licensed for use in ulcerative colitis. There are specific agents that have been developed against CCR9 (CCX282B), MaDCAM-1, and VAP-1; currently an open-label phase II clinical trial is underway evaluating BTT1023, a VAP-1 inhibitor, in PSC. 85 
Manipulating Gut Microbiome Antibiotics
Antibiotic therapy has undergone resurgence in recent years as a potential therapy in PSC, after a few small trials and case series using agents such as vancomycin, metronidazole, and/ or minocycline dating 20 to 50 years ago.
A possible mechanism in which antibiotics may have a role is by altering the gut microbiota and thereby reducing exposure of the biliary epithelium to pathogenic antigens. The "leaky gut" theory, with increased translocation of colonic bacteria and endotoxins, possibly due to concomitant IBD, to the liver via the portal vein, has been suggested to be important in the pathogenesis of PSC. There are numerous pathogen recognition receptors in cholangiocytes, such as nucleotide-binding oligomerization domain (NODs) and all known Toll-like receptors (TLRs). These receptors can recognize pathogen associated molecular patterns (PAMPs) in the bile, which may have been secreted into the canaliculi (from the portal circulation) or from ascending infection. 86, 87 In turn, this leads to increased expression of a variety of innate immune response genes including profibroinflammatory mediators, and ultimately development of hepatobiliary inflammation and fibrosis. This theory is supported by early rat models of small bowel bacterial overgrowth producing PSClike biliary inflammation and strictures.
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The largest study of antibiotics in PSC compared metronidazole (MTZ) and UDCA acid to MTZ alone for 36 months in 80 patients. 90 The addition of MTZ to UDCA therapy significantly improved liver function tests, the Mayo Risk Score, and liver histology scores, with a trend toward inhibition of progression of ERCP changes. A subsequent small pilot study demonstrated a benefit of both low-and high-dose vancomycin as compared with low-or high-dose MTZ, with particular efficacy of lowering ALP (40-43% reduction at 12 weeks), and with fewer side effects. 91 Finally, a recent open-label pilot study of 16 PSC patients treated with rifaximin, a nonabsorbed antibiotic, for 12 weeks failed to show an ALP reduction, and 3 patients withdrew due to adverse events.
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There is an ongoing trial evaluating the efficacy of vancomycin in children with PSC, with a scientific exploratory side arm evaluating the effects of vancomycin on the microbiota and immune system in these patients.
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Fecal Microbiota Transplantation
Also in planning stages is a clinical trial of fecal microbiota transplantation (FMT) in patients with PSC.
94 This is an exciting and novel therapy, based on the assumption that the microbiome in PSC is unique and potentially contributory to the pathogenesis of the disease, research on which is currently active in several centers around the world. Fecal microbiota transplantation has an established role in Clostridium difficile-associated diarrhea, where dysregulation of the microbiome is a key etiological factor, and is also currently being trialed in IBD.
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Endoscopic Intervention Biliary Dilatation and Stenting
Another aspect of the management of patients with PSC is how to investigate and treat dominant strictures. Ten to 50% of patients develop a dominant stricture during the course of their disease, which is defined as stenoses < 1.5 mm in diameter in the common bile duct and < 1 mm in the right and left hepatic duct. 4 It is established that patients who develop a dominant stricture have a worse prognosis than those who do not. 96 There are risks associated with performing an endoscopic retrograde cholangiopancreatography (ERCP)-both for the purposes of investigating for malignancy with biliary brushings for cytology and fluorescence in situ hybridization, as well as endoscopic dilatation and stenting. Therefore, it is often recommended to only investigate and intervene when there is significant cholestasis and/or a change in the clinical picture. On the other hand, there is some evidence that intervention with dilatation and/or stenting may possibly improve prognosis.
97,98
Additionally, it is not clear whether one should simply perform a balloon dilatation or insert a temporary biliary stent. There is a current randomized clinical trial in progress, entitled DILSTENT2 (Multicenter Randomized Trial Comparing Short-Term Stenting versus Balloon Dilatation for Dominant Strictures in Primary Sclerosing Cholangitis), comparing reintervention free survival between these two groups which hopefully will help guide future endoscopic interventions.
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Topical Mitomycin C
Another endoscopic intervention is a current trial evaluating topical therapy with intrabiliary instillation of mitomycin C. 100 Mitomycin C is an aziridine-containing a chemotherapeutic agent that is currently used intravenously and topically for a variety of cancers. It has been used to prevent scar formation following varied surgical interventions.
101,102
Mitomycin C's mechanism of action is to slow fibroblast cell division and proliferation, thereby reducing scar formation. The biliary strictures in PSC have a similar pathophysiology to strictures treated with mitomycin C elsewhere, and therefore may have a potential role in PSC. The primary aim of the study is to determine the efficacy of mitomycin C intrabiliary bolus on survival and the progression of PSC.
Conclusion
Primary sclerosing cholangitis remains a difficult condition to manage with an unmet need for effective therapy. Designing and carrying out clinical trials in PSC can be challenging, but the productive collaboration between researchers and the pharmaceutical industry has led to a large number clinical trials either in planning or underway in PSC. There are several potential pathways that can be targeted therapeutically, such as antifibrotics, alteration of bile acid composition, manipulation of the gut microbiome, attenuating the immune response, and endoscopic therapies. It is likely that an effective drug therapy for PSC will become available over the next decade. 
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